Renalytix inks partnership with Singing River Health System
Renalytix (Reg S)
8.00p
16:55 07/11/24
Renalytix announced a partnership with Singing River Health System to deploy ‘KidneyIntelX’ informed care management on Monday, to improve kidney health in individuals with type-2 diabetes and early-stage chronic kidney disease.
FTSE AIM 100
3,556.98
14:50 08/11/24
FTSE AIM All-Share
734.52
14:50 08/11/24
Health Care Equipment & Services
10,335.71
14:35 08/11/24
The AIM-traded firm said its KidneyIntelX platform would enable Singing River's primary and specialty care providers to easily identify and understand a person's kidney health risks, implement medication and nutrition management, and provide educational intervention on a timely basis.
It described Singing River as a “mission-driven” healthcare provider with locations across the Mississippi Gulf Coast - a region with one of the highest rates of diabetes in the United States.
The partnership between Singing River and Renalytix would focus on improving health outcomes and reducing healthcare costs in the high-risk population, by driving early detection and providing informed care in seeking to delay disease progression and prevent unnecessary dialysis starts.
About 25% of Mississippi's three million residents were currently enrolled in Medicaid health benefits, Renalytix noted, with reports estimating the state's direct and indirect costs of diabetes and its associated conditions such as chronic kidney disease as high as $3.4bn annually.
Recent data also showed that Mississippi continued to be one of the worst states at providing better outcomes and access to healthcare in the Black and Latinx communities, who were already at an increased risk of developing diabetes and chronic kidney disease.
“From the beginning, Renalytix has been committed to taking immediate action to mitigate racial and economic disparities in kidney disease care,” said company president Tom McLain.
“In addition to our new partnership with Singing River, we have secured provider agreements with 27 state Medicaid programs.
“We believe that precision medicine approaches, including KidneyIntelX, will ensure that the right treatment gets to the right patients, regardless of population type, economic status or health insurance coverage.”
Singing River Health System was Renalytix’s first partner along the Gulf Coast.
The company said the health system expansion of KidneyIntelX was also supported by the recent launch within the General Services Administration, which granted a 10-year government-wide contract for KidneyIntelX, which was also covered under numerous commercial insurance programmes.
At 1203 GMT, shares in Renalytix were up 2.2% in London, at 557p.